WEST DES MOINES, IA--(Marketwired - Jun 10, 2016) - Spotlight Innovation Inc. (OTCQB: STLT) announced today that it has finalized plans for entering into an agreement with Maitland Labs, based in Orlando, Florida, to establish its drug production and product development facilities at Maitland Lab's sterile fill drug production plant, currently under construction. The facility is scheduled to be operational in September 2016, and will be FDA registered and compliant with Good Manufacturing Practice standards. Spotlight Innovation will also use the facility to produce products for use in pre-clinical testing and for its clinical trials.

Paul Reid, PhD, Spotlight Innovation's Director of Product Development, said, "As we continue to move forward with our pre-clinical and clinical trials, the opportunity to be based in a state-of-the-art, first-in-class processing facility will offer us consistency and greater efficiency in the production and delivery of clinical samples, and future manufacturing capability."

About Spotlight Innovation Inc.

Spotlight Innovation Inc. (OTCQB: STLT) identifies and acquires rights to innovative and proprietary platform technology candidates with a focus on cancer drugs and related treatment therapies, solutions for infectious disease, and other specialty and unique opportunities. Access to platform technology candidates is accomplished via our extensive relationships with many leading academic institutions and other sources. We provide value-added development capability and funding in order to accelerate development progress. When commercially significant benchmarks have been achieved, we will partner with proven market leaders via sale, out-license or strategic alliance. For more information, visit www.spotlightinnovation.com or follow us on www.twitter.com/spotlightinno.

Forward Looking Statements

Statements in this press release that are not purely historical are forward-looking statements. Forward-looking statements herein include statements regarding Spotlight Innovation's efforts to develop and commercialize its various technologies. Actual outcomes and actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the potential failure to enter into the agreement with Maitland Labs, the inability to finance the planned development of the technologies, the inability to hire appropriate staff to develop the technologies, unforeseen technical difficulties in developing the technologies, the inability to obtain regulatory approval for human use, competitors' therapies proving to be more effective, cheaper or otherwise more preferable, the inability to market a product, all of which could, among other things, delay or prevent product release, as well as other factors expressed from time to time in Spotlight Innovation's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Spotlight Innovation's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release and Spotlight Innovation undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Contact Information:

Press Contact
Rene Erickson
Spotlight Innovation Inc.

Investor Contact
Bob Woods
CEOcast, Inc.